Publication illustrates the clinical benefit of combining PreTRM Â® testing with evidence-based interventions to improve neonatal health and reduce total health costs
Positive impact on preterm births, neonatal intensive care admissions, overall length of hospital stay and a net reduction of $ 54 million in total costs in the analyzed population
SALT LAKE CITY, September 14, 2021 (GLOBE NEWSWIRE) – Serum prognosis Inc., The Pregnancy Company â¢, focused on improving maternal and newborn health by providing innovative information on pregnancy biomarkers to physicians and patients, today announced the publication of a rigorous clinical and economic review using actual data from claims from a large population of Anthem-affiliated health plans. to assess the potential value of the PreTRMÂ® testing and treatment strategy.
The study conservatively modeled the PreTRMÂ® strategy, consisting of proactive, evidence-based testing and interventions, in Anthem claim data from individual and employer-sponsored plans, and showed both improved neonatal outcomes and reduced immediate and long-term treatment costs associated with preterm birth. , compared to routine care. These findings were published in the peer-reviewed journal ClinicoEconomics and Outcomes Research in an article titled “Cost-effectiveness of a proteomic test for the prediction of preterm birth.”
“The publication of this data adds to the growing body of evidence supporting the effectiveness of Sera’s testing and treatment strategy in identifying women at risk for bPST and enabling evidence-based interventions to reduce the risk.” , thereby improving pregnancy outcomes while reducing the economic burden on payers and health care systems, âsaid Gregory C. Critchfield, MD, MS, president and CEO of Sera Prognostics. âWe look forward to discussing the implications of this data as we engage with employers and payers in our efforts to improve pregnancy outcomes and reduce healthcare costs through expanded access to the PreTRMÂ® test. “
Study analysis was conducted by Sera in partnership with HealthCore, using claims data from more than 40,000 pregnant women and infants who were members of individual and employer-sponsored Anthem health plans. The review assessed the PreTRMÂ® testing and treatment strategy by modeling the application of the PreTRMÂ® test during weeks 19 or 20 of pregnancy, and assessed the benefit of proactive interventions consisting of management and monitoring more intensive cases, as well as interventions for women identified as high risk by the test, while usual care was provided for all women without higher PreTRMÂ® risk.
The main conclusions of the analysis include:
20% reduction in preterm births less than 37 weeks gestation 33% reduction in births less than 32 weeks gestation 10% reduction in neonatal intensive care admissions 7% reduction in overall length of stay at the hospital Net savings of $ 863 (gross savings of $ 1,608) per pregnant woman, a $ 54 million reduction in total costs relative to study population
âThe PreTRMÂ® testing and treatment strategy is associated with both better outcomes and reduced total costs, which is rare among modern medical interventions,â said Michael Grabner, senior scientist for HealthCore. “The results were consistent across a wide variety of possible scenarios in terms of test participation, treatment adherence, treatment effectiveness, and accumulated costs.”
Based on the study’s estimated net cost savings for the health care system of $ 863 saved per pregnant woman, the authors estimate that more than $ 850 million could be saved each year in individual-sponsored health plans. and employers in the United States, assuming full use of the test-and-treatment strategy. This is based on an assumption of around 4 million births per year, of which around 50% occur to women with such commercial health insurance, and further assuming that at least half have no risk factors. obvious premature labor.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera’s mission is to provide physicians with essential and early information about pregnancy, enabling them to improve the health of their patients, which translates into reduced health care delivery costs. Sera has a strong portfolio of innovative diagnostic tests focused on early prediction of the risk of preterm birth and other pregnancy complications. Sera’s PreTRMÂ® Precision Medicine Test alerts a physician to the individualized risk of spontaneous preterm delivery during pregnancy, allowing for earlier proactive interventions in women at higher risk. Sera Prognostics is located in Salt Lake City, Utah.
About premature birth
Premature birth is defined as any birth before 37 weeks gestation and is the leading cause of illness and death in newborns. The March of Dimes 2020 report shows that of about 3.8 million babies born each year in the United States, more than one in ten are born prematurely. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory disease, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the life of the children concerned. The annual health care costs for managing the short- and long-term complications of prematurity in the United States have been estimated at around $ 25 billion for 2016.
About the PreTRMÂ® test
The PreTRMÂ® test is the only widely clinically validated, commercially available blood biomarker test that provides early, accurate and individualized prediction of the risk of spontaneous preterm delivery in asymptomatic single pregnancies. The PreTRMÂ® test measures and analyzes blood proteins that are highly predictive of prematurity. The PreTRMÂ® test allows physicians to identify, during the 19th or 20th week of pregnancy, which women are at increased risk of preterm delivery, allowing for more informed and personalized clinical decisions based on the individual risk of pregnancy. every woman. The PreTRMÂ® test is ordered by a healthcare professional.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc in the United States and / or other countries.
Safe Harbor Declaration
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to engagement with employers and payers to potentially expand access to the PreTRMÂ® test; estimates of over $ 850 million to be saved each year assuming full adoption of the risk detection and treatment strategy; and the company’s strategic guidelines under the heading âAbout Sera Prognostics, Inc.â These âforward-looking statementsâ are based on management’s current expectations regarding future events and are subject to a number of risks and considerations. ‘uncertainties that could cause actual results to differ materially and adversely from those stated or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation and the potential need to raise more capital; income from the PreTRM test representing almost all of the Company’s income to date; the need for broad scientific and commercial acceptance of the PreTRM test; a concentrated number of hardware customers; our ability to introduce new products; potential competition; our exclusive biobank; critical suppliers; the ongoing COVID-19 pandemic and its impact on our operations, as well as the activities or operations of third parties with whom we do business; estimates of the total addressable market opportunity and market growth forecasts; potential coverage and reimbursement by a third party payment; the new reimbursement methodologies applicable to the PreTRM test, including the new CPT codes and the payment rates for these codes; changes in FDA regulations on lab-developed tests; intellectual property rights protecting our tests and our market position; and other factors discussed under the heading âRisk Factorsâ contained in our final prospectus on Form S-1, which was filed with the Securities and Exchange Commission on July 14, 2021, as well as any updates to these factors from time to time. in our quarterly reports on Form 10-Q, annual reports on Form 10-K or routine reports on Form 8-K. All information contained in this press release is as of the date of publication, and the Company does not undertake to update this information, except as required by law.
Investor contact Peter DeNardo, CapComm Partners [email protected] +1 (415) 389-6400